Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008.

During the first half of 2008, ThromboGenics has achieved a number of key milestones which have positioned the Company to successfully pursue the next stage of its corporate strategy. In this period, ThromboGenics signed a high value strategic alliance with Roche for its novel anti-cancer product TB-403 and has seen important new clinical data for its lead product, microplasmin, in patients with back of the eye disease. Given this progress, ThromboGenics is confident that the next twelve months will see further significant shareholder value being generated as it continues to maximise value from its product pipeline.
2008 highlights

Partnership

- Major partnering deal: In June, ThromboGenics and its co-development

partner BioInvent signed a strategic alliance deal with Roche for its

novel anti-cancer agent, TB-403 (anti-PIGF). Under the terms of the

agreement ThromboGenics and BioInvent received an upfront payment of

EUR50 million and could potentially share up to EUR450 million in

milestone payments as well as double digit royalties. TB-403 is a novel

monoclonal antibody which blocks Placental Growth Factor (PIGF), one of

the growth factors responsible for the development of new blood

vessels. TB-403 is being developed as an anti-cancer agent, and is

currently in Phase I of clinical development. It acts by selectively

inhibiting tumor growth by blocking its blood supply without affecting

normal tissues.

Clinical Highlights

- TB-403 : Positive results announced in first Phase Ia study

with TB-403 and start of Phase Ib study in late stage cance
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 The College ... first private college in the Mid-Hudson Region to be ... now begin accepting applications from qualified “high-technology” businesses that ... are very pleased to have been selected for the ... Cuomo’s transformative initiative to stimulate economic development in New ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary ... by the Jeffrey Epstein VI Foundation , have shown ... identified for elimination. These aggressive cells are the driver mutations ... topological map of what to look for when examining tumors, ... tumor cells can be extracted from biopsy, it,s very difficult ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... REYKJAVIK, Iceland, August 10 deCODE genetics,(Nasdaq: ... the,quarter ended June 30, 2009. A conference call to ... will be webcast live tomorrow,Tuesday, August 11, at 8:00am ... , The financial results presented ...
... BOZEN, Italy, August 10 , ... Health Robotics today announced that it has signed ... Robot. The,agreement enables McKesson to achieve its goal of safely, ... "We are very pleased to have ...
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... sale of approximately 2.28 million shares of its common stock ... stock for gross proceeds of approximately $15.0 million on August ... per unit (each unit consisting of one share and a ...
Cached Biology Technology:deCODE genetics Announces Second Quarter 2009 Financial Results 2deCODE genetics Announces Second Quarter 2009 Financial Results 3deCODE genetics Announces Second Quarter 2009 Financial Results 4deCODE genetics Announces Second Quarter 2009 Financial Results 5deCODE genetics Announces Second Quarter 2009 Financial Results 6deCODE genetics Announces Second Quarter 2009 Financial Results 7deCODE genetics Announces Second Quarter 2009 Financial Results 8deCODE genetics Announces Second Quarter 2009 Financial Results 9deCODE genetics Announces Second Quarter 2009 Financial Results 10McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3Oncothyreon announces closing of $15.0 million registered direct financing 2
(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
(Date:8/21/2014)... darkness use a previously unknown process for harvesting energy ... by a Penn State University scientist has discovered. The ... improving plant growth, harvesting energy from the Sun, and ... Erie and other lakes worldwide. A paper describing the ... Express edition of the journal Science on ...
(Date:8/21/2014)... Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ... World,s Most Influential Scientific Minds 2014," a comprehensive ... a web resource for science metrics and research performance ... the most influential "are performing and publishing work that ... their science," according to a Thomson Reuters statement. Researchers ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... scientists will swarm to the Austin Convention Center from ... the Entomological Society of America. Members of the ... for a complimentary press pass by writing to ... Topics covered during the meeting will include bed bugs, ...
... significant problems facing the world,s marine environments. Yet in the ... tons of plastic litter enter the ocean each year. ... of Law,s Emmett Center on Climate Change and the Environment ... sources and impacts of plastic marine litter and offers domestic ...
... devoted to getting more Hispanics into the fields ... honored a scientist at the Energy Department,s National ... Technical Achievement Award. Santiago Carlos Grijalva is ... Center at the Energy Systems Integration Facility (ESIF), ...
Cached Biology News:UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 2UCLA report urges new global policy effort to tackle crisis of plastic litter in oceans 3NREL researcher honored with Hispanic STEM award 2NREL researcher honored with Hispanic STEM award 3
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... For our novel expression vectors, we in-troduced a ... controls: (i) at tran-scriptional level at the T7 ... level by amplifying the plasmid copy number, The ... that it retains practically all of the outstanding ...
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
... High-throughput protein crystallography involves using many of ... (HTS). The liquid handling requirements are similar ... traditional crystallography plates have 24 or 48 ... microliters. For higher throughput, the number of ...
Biology Products: